Buy or sell Medeor Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Medeor Therapeutics Stock

Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.


San Mateo CA, US

Total Funding


About Medeor Therapeutics Stock

Medeor Therapeutics is a biotechnology company that dedicates to the discovery, development and commercialization of transformative and personalized cellular immunotherapies. Its growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Its pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). The company holds exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.

Funding History

November 2017$57.0M


Co-Founder, President and CEO

Steven Deitcher

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Medeor Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: